Companies and laboratories

NEOMatrix is a spin-off company from Takis, a Biotech with a scientific group with more than 10 years experience in drug discovery, including the validation of new targets for the treatment of chronic viral diseases and cancer and to a number of IND/CSA filings in the areas of virology and oncology. NEOMatrix’s team is constituted by researchers who were leading Cancer Vaccine programs in Merck Research Laboratories before foundation of Takis and within Takis. The team is recognized for the conception and implementation of a number of innovative technologies with the goal to improve in vivo gene transfer, regulation of gene expression and immunogenicity. The program for development of personalized Therapeutic Cancer Vaccines was started in Takis 4 years ago and recently led to foundation of the spin-off NEOMatrix to look for financial support for its clinical development and exploitation.